Surrey Heartlands

Joint Formulary & PAD

Rivastigmine - Dementia

You are here : Home > Formulary Search > Rivastigmine - Dementia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
  • Patches
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Important

Rivastigmine is BLUE (with information sheet) for those patients who are stable and suitable for discharge from specialist care.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

 

Status 2

Amber
Formulations :
  • Capsules
  • Patches
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Important

AMBER shared care applies for patients that are not suitable for discharge and who will continue to receive follow up by SABP.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

Documentation

Guidelines (Local)
Dementia Treatment Pathway - Feb 2019
Guidelines (Local)
Memantine in combination with AChE - prescribing guidance for GPs - Mar 19
Shared Care
Donepezil, Galantamine and Rivastigmine BLUE Prescribing Information sheet - March 2019
Shared Care
Acetylcholinesterase Inhibitors for Dementia - Shared Care Amber - July 2015

PAD Profile

ChemicalSubstance :
Rivastigmine
Indication :
Dementia
Group Name :
Keywords :
AChE Inhibitors, acetylcholinesterase inhibitors, alzheimers disease, alzheimers dementia, Alzheimer's disease, Lewy Body dementia, Vascular dementia, Parkinson's dementia
Brand Names Include :
Exelon patch, Nimvastid, Almuriva, Alzest, Prometax, Voleze, Zeyzelf, Almuriva
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Dementia
Supporting Documents :
4
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Rivastigmine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Dementia.

Committee Recommendations (2)

02 Jul 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Follow link to Shared Care Principles and Communication letters Shared Care principles and Communication letters

06 Mar 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Generic donepezil is the 1st-line acetylcholinesterase inhibitor for mild to moderate Alzheimer's disease.  Galantamine or rivastigmine are alternative AChE inhibitors. Rivastigmine is also a treatment option for dementia with Lewy bodies, vascular dementia and Parkinson's dementia.
See below for the local treatment pathways


Rivastigmine has been recommended as BLUE (with information sheet) for those patients who are stable and suitable for discharge from specialist care.


AMBER shared care  will apply for the patients that are not suitable for discharge and who will continue to receive follow up by SABPT


Note - the branded rivastigmine, Exelon, has been assigned a BLACK traffic light status and should not be prescribed